A slow drug-release system has proven highly effective in treating certain bladder cancer patients whose tumors were previously unresponsive to therapy. A new targeted drug delivery system known as TA ...
Pioneering CRISPR trial shows single infusion permanently lowers bad cholesterol by 50% in patients who don't respond to medication.
Q3 2025 Earnings Call Transcript November 7, 2025 ALX Oncology Holdings Inc. misses on earnings expectations. Reported EPS is ...
Abivax delivered outstanding phase 3 results for obefazimod in ulcerative colitis, with a 16.4% placebo-adjusted clinical ...
Viking Therapeutics witnessed a significant boost in its share price following the release of compelling data from a ...
UCSF's Chancellor Hawgood urged transition to a "Second Curve" of innovation, leveraging philanthropy, new infrastructure, ...
Intellia Therapeutics has acknowledged the death of the elderly patient hospitalized last week in its Phase III trial of assessing nexiguran ziclumeran (nex-z) in transthyretin amyloidosis with ...
Researchers from Rutgers Cancer Institute, New Jersey’s only National Cancer Institute (NCI) - designated Comprehensive ...
Existing frameworks for explainable artificial intelligence (XAI) and AI governance, such as the EU AI Act and the NIST AI ...
SPG302 was well tolerated in a trial, with preliminary data supporting the idea the therapy might slow ALS progression.
SHELTON, CONNECTICUT / ACCESS Newswire / November 3, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs ...
NEWARK, CALIFORNIA / ACCESS Newswire / November 3, 2025 / Protagonist Therapeutics, Inc. (“Protagonist” or the “Company”) announced that clinical data on rusfertide in polycythemia vera, including the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback